{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:46:41Z","timestamp":1794815201590,"version":"4.9.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1627,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["1245-0175"],"award-info":[{"award-number":["1245-0175"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["1245\u20100175"],"award-info":[{"award-number":["1245\u20100175"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although the reno-protective effects of sodium\u2013glucose cotransporter 2 inhibitors are known in patients with heart failure or type 2 diabetes mellitus (T2DM), this effect has not been confirmed in patients with acute myocardial infarction (AMI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The prospective, multicentre, randomized, double-blind, placebo-controlled EMBODY trial investigated patients with AMI and T2DM in Japan. The eligible patients included adults aged 20 years or older, diagnosed with AMI and T2DM, and who could be discharged within 2\u201312 weeks after the onset of AMI. One hundred and five patients were randomized (1:1) to receive once daily 10 mg empagliflozin or placebo within 2 weeks of AMI onset. In this sub-analysis, we investigated the time course of renal functional parameters such as serum creatinine levels and estimated glomerular filtration rate (eGFR) from baseline to Weeks 4, 12, and 24. Ninety-six patients (64 \u00b1 11 years, 78 male) were included in the full analysis (n = 46 and 50 in the empagliflozin and placebo groups, respectively). We used serum creatinine and eGFR as indicators of renal function. In the placebo group, eGFR decreased from 66.14 mL\/min\/1.73 m2 at baseline to 62.77 mL\/min\/1.73 m2 by Week 24 (P = 0.023) but remained unchanged in the empagliflozin group (from 64.60 to 64.36 mL\/min\/1.73 m2, P = 0.843). In the latter group, uric acid improved from 5.8 mg\/dL at baseline to 4.9 mg\/dL at Week 24 (P &amp;lt; 0.001). In the earlier analysis of 56 patients with eGFR \u2265 60 mL\/min\/1.73 m2, the eGFR decreased and the serum creatinine increased from baseline to 24 weeks in the placebo group, significantly different to the empagliflozin group (\u22126.61 vs. +0.22 mL\/min\/1.73 m2, P = 0.008 and +0.063 vs. \u22120.001 mg\/dL, P = 0.030, respectively). The changes in serum creatinine and eGFR from baseline to Week 24 were significantly correlated with those in uric acid in the placebo group (r = 0.664, P &amp;lt; 0.001 and r = \u22120.675, P &amp;lt; 0.001, respectively) but not in the empagliflozin group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Empagliflozin prevented the kidney functional decline in patients with AMI and T2DM, especially those with baseline eGFR \u2265 60 mL\/min\/1.73 m2. Early administration of sodium\u2013glucose cotransporter 2 inhibitors in these patients is considered desirable for renal protection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13509","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T02:14:52Z","timestamp":1625710492000},"page":"4161-4173","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Empagliflozin Confers Reno-Protection in Acute Myocardial Infarction and Type 2 Diabetes Mellitus"],"prefix":"10.1093","volume":"8","author":[{"given":"Kosuke","family":"Mozawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7320-7641","authenticated-orcid":false,"given":"Yoshiaki","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hoshika","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Tara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukichi","family":"Tokita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yodogawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ki","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tsukada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniya","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Chiba Hokuso Hospital , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitaro","family":"Kodani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Tama Nagayama Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunori","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Musashi Kosugi Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shizuoka Medical Center , Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School , 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-0022 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"key":"2026012114222324300_ehf213509-bib-0001","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2026012114222324300_ehf213509-bib-0002","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2026012114222324300_ehf213509-bib-0003","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41440-017-0001-5","article-title":"Clinical features and therapeutic perspectives on hypertension in diabetics","volume":"41","author":"Katayama","year":"2018","journal-title":"Hypertens Res"},{"key":"2026012114222324300_ehf213509-bib-0004","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012114222324300_ehf213509-bib-0005","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012114222324300_ehf213509-bib-0006","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114222324300_ehf213509-bib-0007","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114222324300_ehf213509-bib-0008","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114222324300_ehf213509-bib-0009","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2026012114222324300_ehf213509-bib-0010","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13300-018-0480-7","article-title":"Effect of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: rationale","volume":"9","author":"Kubota","year":"2018","journal-title":"Diabetes Ther"},{"key":"2026012114222324300_ehf213509-bib-0011","first-page":"e362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"2026012114222324300_ehf213509-bib-0012","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"2026012114222324300_ehf213509-bib-0013","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"2026012114222324300_ehf213509-bib-0014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"2026012114222324300_ehf213509-bib-0015","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2026012114222324300_ehf213509-bib-0016","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"Levey","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2026012114222324300_ehf213509-bib-0017","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41440-020-0426-0","article-title":"Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes","volume":"43","author":"Kohagura","year":"2020","journal-title":"Hypertens Res"},{"key":"2026012114222324300_ehf213509-bib-0018","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"2026012114222324300_ehf213509-bib-0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","article-title":"Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"40","author":"Liu","year":"2018","journal-title":"Ren Fail"},{"key":"2026012114222324300_ehf213509-bib-0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","article-title":"Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis","volume":"16","author":"Kanji","year":"2015","journal-title":"BMC Nephrol"},{"key":"2026012114222324300_ehf213509-bib-0021","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"2026012114222324300_ehf213509-bib-0022","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1002\/ehf2.12825","article-title":"Rationale and design of the EMPYREAN study","volume":"7","author":"Motoki","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114222324300_ehf213509-bib-0023","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcjd.2014.05.006","article-title":"Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?","volume":"38","author":"Cherney","year":"2014","journal-title":"Can J Diabetes"},{"key":"2026012114222324300_ehf213509-bib-0024","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"2026012114222324300_ehf213509-bib-0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"2026012114222324300_ehf213509-bib-0026","doi-asserted-by":"crossref","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012114222324300_ehf213509-bib-0027","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00125-009-1268-0","article-title":"Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis","volume":"52","author":"Magee","year":"2009","journal-title":"Diabetologia"},{"key":"2026012114222324300_ehf213509-bib-0028","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13509","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13509","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/5\/4161\/65566136\/eschf_8_5_4161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/5\/4161\/65566136\/eschf_8_5_4161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:27:43Z","timestamp":1769023663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/5\/4161\/8345835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,7,7]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13509","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10]]},"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"2021-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}